ClinicalTrials.gg
CompletedNCT02012218Updated Dec 29, 2015Results posted

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

A Phase 3 interventional study of ADT and Brexpiprazole in Major Depressive Disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 24 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-12-29.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
16th of 24
61 · median 189
Started
2013
with 6 others
Phase 3
16 of 24
none open now
Registered
12th of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 16th largest by enrollment, is one of 7 that started in 2013, is one of 16 in phase 3, and was the 12th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The objectives of this exploratory trial are to evaluate the efficacy, safety, and subjects' subjective satisfaction when switching to adjunctive brexpiprazole in subjects with MDD who have responded inadequately to preceding adjunctive drug therapy.

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Major Depressive Disorder, Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of MDD
  • In current major depressive episode of ≥ 8 weeks in duration and includes an inadequate response to at least 1 adjunctive treatment.
  • Positive history of at least 1 additional failure to an adequate monotherapy antidepressant treatment.
  • HAM-D17 total score≥ 18
  • Currently receiving SSRI of SNRI with adjunctive treatment for at least 6 weeks before screening.
  • Willing to discontinue use of all prohibited psychotropic medications
  • Historical positive serological results for , /C
  • Able to provide written prior to the initiation of any protocol-required procedures
  • Subjects who could potentially benefit from adjunctive treatment with Brexpiprazole

Exclusion criteria

Exclusion Criteria:

  • Sexually active women of
  • Male subjects not practicing 2 different methods of
  • Females who are breastfeeding and/or who have a positive pregnancy test result
  • Subjects who have received ECT for the current major depressive episode.
  • Subjects who have had an inadequate response to ECT
  • Current need for involuntary commitment or who have been hospitalized within 4 weeks of screening
  • Current Axis I ()
  • Current Axis II (DSM-IV-TR)
  • Subjects experiencing hallucinations, delusions, or any psychotic symptomatology in the current major depressive episode.
  • Subjects receiving new onset psychotherapy.
  • Subjects who answer "Yes" on the C-SSRS Suicidal Ideation Item 4, Item 5, or on any of the 5 C-SSRS Suicidal Behavior Items
  • Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days
  • Hypothyroidism or hyperthyroidism
  • neurological, hepatic, renal, metabolic, haematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders
  • Currently treated with insulin for diabetes
  • Uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension
  • Known ischemic heart disease or history of myocardial infarction, congestive heart failure, angioplasty, stenting, or coronary artery bypass surgery
  • Epilepsy or history of seizures
  • Positive drug screen
  • The following laboratory test and results are exclusionary:

    1. ≤ 75,000/mm3
    2. ≤ 9 g/dL
    3. Neutrophils, absolute ≤ 1000/mm3
    4. > 2 ×
    5. ALT > 2 × ULN
    6. CPK > 3 × ULN, unless discussed with and approved by the medical monitor
    7. Creatinine ≥ 2 mg/dL
    8. ≥ 7.0%
    9. Abnormal free T4 (Note: Free T4 is measured only if result for TSH is abnormal.)
    10. ≥ 470 msec for females and ≥ 450 msec for males
  • Treatment with an MAOI or EMSAM within 14 days of the Baseline visit.
  • Use of benzodiazepines and/or hypnotics within 7 days prior to the first dose of IMP
  • Use of oral neuroleptics within 7 days prior or long-acting approved atypical antipsychotics ≤ 1 full cycle plus ½ cycle prior to the first dose of IMP
  • Subjects who would be likely to require prohibited concomitant therapy during the trial.
  • Subjects who previously participated in any prior brexpiprazole trial
  • History of neuroleptic malignant syndrome or serotonin syndrome
  • History of true allergic response to more than one class of medications
  • Prisoners or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
  • Subjects who participated in a clinical trial within the last 180 days or who participated in more than 2 clinical trials within the past year.
  • Any subject who, in the opinion of the investigator or medical monitor, should not participate.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    ADT and Brexpiprazole

    ADT and Brexpiprazole

    Drug: ADT · Drug: Brexpiprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS was used as the primary efficacy assessment of level of depression. The MADRS was administered using the Structured Interview Guide for the MADRS. Detailed instructions were provided.The MADRS consists of 10 items each, with 7 defined grades of severity (ie, 0 to 6, with 0 being the "best" rating and 6 being the "worst" rating). The MADRS total score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score least squares (LS) mean changes from baseline to Week 6 is mentioned below.

    Time frame: Baseline and Week 6

07

Results

Posted Oct 8, 2015

Participant flow

This trial was conducted in 61 participants in 28 trial sites, all of which were located in the United States.

Participant flow — Overall Study
MilestoneGroup 1AGroup 1BGroup 2Group 3Group 4
Started121113196
Completed81011175
Not completed41221
Withdrew: Withdrawal by subject10111
Withdrew: Adverse event10010
Withdrew: Lost to follow-up01100
Withdrew: Protocol specified10000
Withdrew: Protocol deviation10000

Outcome measures

PrimaryMean Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS was used as the primary efficacy assessment of level of depression. The MADRS was administered using the Structured Interview Guide for the MADRS. Detailed instructions were provided.The MADRS consists of 10 items each, with 7 defined grades of severity (ie, 0 to 6, with 0 being the "best" rating and 6 being the "worst" rating). The MADRS total score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score least squares (LS) mean changes from baseline to Week 6 is mentioned below.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Units on a scaleGroup 1AGroup 1BGroup 2Group 3Group 4
Mean Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-12.8 ± 2.26-18.4 ± 2.10-19.5 ± 1.99-19.2 ± 1.59-16.8 ± 2.97
Statistical analysis
  • Group 1A vs Group 1B vs Group 2 vs Group 3 vs Group 4 · Mixed Models Analysis · p = <0.0001 (P-values were calculated according to testing a null hypothesis of zero mean change.)This analysis was conducted using a mixed model repeated measures analysis on observed case data.

Adverse events

Collected over Adverse events were reported from the signing of the informed consent until the end of trial with a safety follow-up of 30 (+2 ) days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1A—0/12 (0%)7/12 (58.3%)
Group 1B—1/11 (9.1%)8/11 (72.7%)
Group 2—0/13 (0%)6/13 (46.2%)
Group 3—0/19 (0%)15/19 (78.9%)
Group 4—0/6 (0%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventGroup 1AGroup 1BGroup 2Group 3Group 4
RhabdomyolysisMusculoskeletal and connective tissue disorders0/121/110/130/190/6
Most frequent other events
Showing 10 of 58
Most frequent other events
EventGroup 1AGroup 1BGroup 2Group 3Group 4
FatigueGeneral disorders1/120/112/133/193/6
AkathisiaNervous system disorders2/120/110/133/190/6
HeadacheNervous system disorders1/121/111/131/191/6
SomnolenceNervous system disorders0/120/111/132/191/6
SedationNervous system disorders0/120/111/130/191/6
Initial insomniaPsychiatric disorders0/121/110/130/191/6
Dry mouthGastrointestinal disorders2/120/111/132/190/6
Abdominal distensionGastrointestinal disorders0/120/110/130/191/6
NasopharyngitisInfections and infestations0/120/110/130/191/6
Atrioventricular block first degreeCardiac disorders0/120/110/130/191/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Group 1AGroup 1BGroup 2Group 3Group 4Total
Mean50.2 ± 8.1341.8 ± 13.5748.5 ± 12.2044.1 ± 13.6441.7 ± 13.5945.6 ± 12.44
Sex: Female, Male
Sex: Female, Male(Participants)Group 1AGroup 1BGroup 2Group 3Group 4Total
Female771115343
Male5424318
08

Study locations

24 sites
  • Collaborative NeuroScience Network, Inc.
    Garden Grove, California 92845, United States
  • Viking Clinical Research, Ltd.
    Temecula, California 92591, United States
  • Clinical Neuroscience Solutions Pharmacology
    Orlando, Florida 32806, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • Goldpoint Clinical Research
    Indianapolis, Indiana 46260, United States
  • Alpine Clinic
    Lafayette, Indiana 47905, United States
  • Pharmasite Research
    Baltimore, Maryland 21208, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Coastal Research Associates, Inc.
    Weymouth, Massachusetts 02190, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • St. Louis Clinical Trials
    St. Louis, Missouri 63118, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Behavioral Medical Research of Staten Island
    Staten Island, New York 10305, United States
  • Richard H. Weisler, MD, PA
    Raleigh, North Carolina 27609, United States
  • Midwest Clinical Research Center MCRC
    Dayton, Ohio 45417-3445, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73116, United States
  • Oregon Center for Clinical Investigations, Inc.
    Portland, Oregon 97210, United States
  • Oregon Center for Clinical Investigations, Inc.
    Salem, Oregon 97301, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Lincoln Research, LLC
    Lincoln, Rhode Island 02865, United States
  • Research Strategies of Memphis, LLC
    Memphis, Tennessee 38119, United States
  • Future Search Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • NeuropsychiatricAssociates
    Woodstock, Vermont 05091, United States
  • Frontier Institute
    Spokane, Washington 99204, United States
09

References and documents

Publications

  • Weiss C, Meehan SR, Brown TM, Gupta C, Morup MF, Thase ME, McIntyre RS, Ismail Z. Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews. J Patient Rep Outcomes. 2021 Dec 11;5(1):128. doi: 10.1186/s41687-021-00380-4. PubMed 34894307 ↗
  • Fava M, Okame T, Matsushima Y, Perry P, Weiller E, Baker RA. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning. Int J Neuropsychopharmacol. 2017 Jan 1;20(1):22-30. doi: 10.1093/ijnp/pyw087. PubMed 27784751 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2013
First posted
Dec 16, 2013
Start
Nov 2013
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Oct 8, 2015
Last update
Dec 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02012218
Responsible party
Sponsor
First posted
Dec 16, 2013
Start date
Nov 2013
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Oct 8, 2015
Last update
Dec 29, 2015

Study contacts

Junichi Hashimoto, PhD
study director · Otsuka Pharmaceutical Co., Ltd Japan (OPCJ)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion